Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.75 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.75 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL28151034 | 1.00 | TSHR (0.75) | TSHRNAPRTTDP1NOTUMCYP11B2 | |
| Pyridine SCHEMBL6114733 | 1.00 | TSHR (0.75) | TSHRNAPRTTDP1NOTUMCYP11B2 | |
| Pyridine SCHEMBL5661698 | 1.00 | — | — | |
| Pyridine SCHEMBL6952793 | 1.00 | TSHR (0.75) | TSHRNAPRTTDP1NOTUMCYP11B2 | |
| Cyclooctane SCHEMBL9180329 | 1.00 | TSHR (0.75) | TSHRNAPRTTDP1NOTUMCYP11B2 | |
| Pyridine SCHEMBL28150051 | 1.00 | TSHR (0.75) | TSHRNAPRTTDP1NOTUMCYP11B2 | |
| Cycloheptane SCHEMBL9426206 | 1.00 | TSHR (0.75) | TSHRNAPRTTDP1NOTUMCYP11B2 | |
| Pyridine SCHEMBL11129549 | 0.96 | TSHR (0.69) | TSHRNAPRTTDP1NOTUMCYP11B2 | |
| Pyridine SCHEMBL8857956 | 0.96 | TSHR (0.69) | TSHRNAPRTTDP1NOTUMCYP11B2 | |
| Pyridine SCHEMBL29290888 | 0.96 | TSHR (0.69) | TSHRNAPRTTDP1NOTUMCYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485663-B2 | Carvedilol | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-02-03 | — | — | US | claimed |
| US-20040225132-A1 | Carvedilol | HILDESHEIM JEAN (IL) | 2004-11-11 | — | — | US | claimed |
| US-20020143045-A1 | Carvedilol | TEVA PHARMACEUTICALS USA, INC. | 2002-10-03 | — | — | US | claimed |
| CN-106535865-B | Lactone-containing compositions for malodor elimination | 高砂香料工业株式会社 | 2020-06-23 | — | — | CN | disclosed |
| WO-2019182015-A1 | ALGINIC ACID DERIVATIVE BONDED TO NONSTEROIDAL ANTI-INFLAMMATORY COMPOUND | 持田製薬株式会社 | 2019-09-26 | — | — | WO | disclosed |
| US-8716472-B2 | Tripodal cyclohexane derivatives and their use as carbohydrate receptors | UNIVERSITY OF ROCHESTER (US) | 2014-05-06 | — | — | US | disclosed |
| WO-2011051975-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF PURE EPROSARTANAND ITS PHARMACEUTICAL ACCEPTABLE SALTS | MATRIX LABORATORIES LTD (IN) | 2011-05-05 | — | — | WO | disclosed |
| US-20110054186-A1 | PROCESS FOR EPROSARTAN INTERMEDIATE | HETERO RESEARCH FOUNDATION (IN) | 2011-03-03 | — | — | US | disclosed |
| EP-2257540-A2 | IMPROVED PROCESS FOR EPROSARTAN INTERMEDIATE | Hetero Research Foundation (IN) | 2010-12-08 | — | — | EP | disclosed |
| US-20100137613-A1 | PROCESS FOR EPROSARTAN | HETERO DRUGS LIMITED (IN) | 2010-06-03 | — | — | US | disclosed |
| WO-2010023688-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF EPROSARTAN | MATRIX LABORATORIES LIMITED (IN) | 2010-03-04 | — | — | WO | disclosed |
| US-6699997-B2 | REACTING 4-(OXIRAN-2-YLMETHOXY)-9H- CARBAZOLE WITH 2-(2-METHOXYPHENOXY)ETHYLAMINE TO PRODUCE CARVEDILOL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-03-02 | — | — | US | disclosed |
| US-20020143045-A1 | Carvedilol | TEVA PHARMACEUTICALS USA, INC. | 2002-10-03 | — | — | US | disclosed |
| EP-0970073-A4 | PROCESS FOR PREPARING EPROSARTAN | SMITHKLINE BEECHAM CORP (US) | 2001-01-24 | — | — | EP | disclosed |
| US-6172237-B1 | Process for preparing eprosartan | SMITHKLINE BEECHAM CORPORATION | 2001-01-09 | — | — | US | disclosed |
| EP-0970073-A1 | PROCESS FOR PREPARING EPROSARTAN | SMITHKLINE BEECHAM CORPORATION (US) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998035963-A1 | PROCESS FOR PREPARING EPROSARTAN | SMITHKLINE BEECHAM CORPORATION (US) | 1998-08-20 | — | — | WO | disclosed |
| US-5101067-A | Chemical intermediates for pyridinedicarboxylic acid esters, herbicides | WACKER-CHEMIE GMBH (DE) | 1992-03-31 | — | — | US | disclosed |
| US-5008392-A | Reacting 2,3-dihalomaleic acid esters with ammonia or salts, reacting product with alpha, B-unsaturated aldehydes or ketones | WACKER-CHEMIE GMBH (DE) | 1991-04-16 | — | — | US | disclosed |
| EP-0057577-B1 | METHOD FOR THE BENEFICIATION, LIQUEFACTION AND RECOVERY OF COAL AND OTHER SOLID CARBONACEOUS MATERIALS AND BENEFICIATED COAL PRODUCTS | THE STANDARD OIL COMPANY (US) | 1986-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110054186-A1 | PROCESS FOR EPROSARTAN INTERMEDIATE | PTGER1, PTGER4, PDGFRA | TSHR 226/4885NAPRT 1261/4885TDP1 2656/4885 |
| US-20100137613-A1 | PROCESS FOR EPROSARTAN | PTMA, PTGER1, PDGFRA | TSHR 453/4885NAPRT 1886/4885TDP1 2935/4885 |
| US-20040225132-A1 | Carvedilol | REN, ADRB1, ADRB2 | TSHR 3165/4885NAPRT 2158/4885TDP1 4010/4885 |
| US-20020143045-A1 | Carvedilol | REN, ADRB1, ADRB2 | TSHR 3165/4885NAPRT 2158/4885TDP1 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.